GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Scientific rationale for pursuit of
a DIC/sepsis indication for ATryn


Primary support

“Treatment Effects of High-Dose
Antithrombin Without Concomitant
Heparin in Patients With Severe
Sepsis With/Without Disseminated
Intravascular Coagulation”
Kienast J et al
J Thromb Haemost. 2006 Jan;4(1):90-7
Abstract: #msg-9313165.
Paper: http://ihub.concedere.net/Key_DIC_sepsis_article.pdf


Ancillary support

[Aside from the above, the following papers are
the most relevant published works according to
the presentation at GTC’s 2006 annual meeting.
Please see #msg-14363731 for supplementary
references.]

“Benefit/Risk Profile of High-Dose
Antithrombin in Patients with Severe
Sepsis Treated With and Without
Concomitant Heparin”
Hoffmann, JN et al
Thromb Haemost. 2006 May;95(5):850-6.
Abstract: #msg-10993909.

“Antithrombin for Severe Sepsis?
Try Again But Without the Heparin!”
Jilma, B
Thromb Haemost. 2006 May;95(5):755.
(No abstract)

“High-Dose Antithrombin in the Treatment
of Severe Sepsis in Patients with a High
Risk of Death: Efficacy and Safety”
Wiedermann CJ
Crit Care. 2006 Feb 34(2):285-92.

“Recombinant Human Antithrombin Inhibits
Thrombin Formation and Interleukin-6
Release in Human Endotoxemia”
Leitner JM et al
Clin Pharmacol Ther. 2006 Jan;79(1):23-34.
Abstract: #msg-9313029.

[The original KyberSept study]
“High-Dose Antithrombin in Severe
Sepsis: A Randomized Controlled Trial”
Warren B et al
JAMA 2001 286:1869
http://scalpel.stanford.edu/articles/AT3.pdf